| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 314 | 613 | 729 | 856 | 980 | 815 | 931 | 897 | 802 | 692 | 791 | 805 | 1,266 | 478 | 530 | 862 | 662 | 696 | 842 | 760 | 641 | 839 | 834 | 845 | 922 | 702 | 744 | 805 | 952 | 954 | 954 | 933 | 1,014 | 939 | 1,035 | 1,075 | 1,030 | 4,354 | 1,195 | 1,160 | 1,206 | 1,128 |
| Expenses | 274 | 564 | 628 | 728 | 855 | 676 | 730 | 602 | 577 | 595 | 688 | 627 | 604 | 448 | 496 | 516 | 572 | 612 | 610 | 574 | 772 | 648 | 662 | 712 | 773 | 850 | 818 | 833 | 944 | 1,002 | 844 | 892 | 879 | 802 | 1,054 | 886 | 888 | 866 | 987 | 946 | 1,000 | 910 |
| EBITDA | 40 | 50 | 101 | 128 | 125 | 140 | 201 | 295 | 225 | 97 | 103 | 178 | 663 | 30 | 34 | 346 | 90 | 84 | 232 | 187 | -131 | 191 | 173 | 133 | 149 | -148 | -75 | -28 | 8 | -49 | 110 | 41 | 135 | 136 | -18 | 189 | 142 | 3,488 | 209 | 215 | 206 | 218 |
| Operating Profit % | 11 % | 3 % | 7 % | 13 % | 8 % | 14 % | 16 % | 17 % | 15 % | 10 % | 11 % | 16 % | 10 % | 5 % | 5 % | 10 % | 7 % | 11 % | 15 % | 22 % | -25 % | 17 % | 17 % | 14 % | 15 % | -23 % | -13 % | -5 % | -9 % | -7 % | 6 % | -3 % | 11 % | 14 % | -5 % | 12 % | 15 % | 18 % | 15 % | 18 % | 16 % | 19 % |
| Depreciation | 20 | 32 | 36 | 40 | 39 | 42 | 44 | 31 | 38 | 35 | 37 | 38 | 44 | 29 | 31 | 28 | 30 | 43 | 42 | 44 | 45 | 49 | 53 | 53 | 52 | 55 | 57 | 61 | 61 | 60 | 62 | 60 | 61 | 60 | 60 | 49 | 48 | 47 | 49 | 48 | 49 | 49 |
| Interest | 15 | 28 | 34 | 54 | 62 | 56 | 58 | 44 | 48 | 52 | 49 | 50 | 46 | 17 | 17 | 22 | 23 | 35 | 40 | 40 | 40 | 37 | 37 | 35 | 42 | 42 | 44 | 42 | 50 | 55 | 68 | 58 | 81 | 76 | 79 | 70 | 71 | 73 | 74 | 52 | 50 | 48 |
| Profit Before Tax | 33 | 19 | 69 | 68 | 24 | 41 | 98 | 220 | 140 | 10 | 17 | 90 | 573 | -16 | -14 | 296 | 37 | 6 | 149 | 104 | -217 | 105 | 83 | 46 | 55 | -244 | -175 | -131 | -103 | -163 | -20 | -78 | -7 | 0 | -157 | 70 | 23 | 3,369 | 86 | 114 | 106 | 122 |
| Tax | 22 | 9 | 34 | 10 | 20 | 9 | 13 | 24 | 8 | 4 | 5 | 2 | -5 | -14 | -6 | -0 | -8 | 3 | 7 | 11 | -11 | 3 | 6 | 11 | 12 | -36 | -7 | -5 | -132 | -28 | -38 | 4 | 7 | 10 | -7 | 16 | 13 | 19 | 14 | 24 | 21 | 17 |
| Net Profit | 11 | 10 | 35 | 58 | 4 | 33 | 85 | 196 | 132 | 6 | 12 | 88 | 578 | -3 | -9 | 296 | 45 | 3 | 142 | 92 | -207 | 102 | 77 | 35 | 44 | -209 | -168 | -127 | 29 | -135 | 19 | -82 | -14 | -9 | -150 | 54 | 10 | 3,350 | 72 | 90 | 86 | 106 |
| EPS in ₹ | 1.91 | 1.34 | 4.44 | 6.59 | 1.74 | 2.91 | 8.29 | 20.96 | 12.57 | 0.06 | 0.96 | 9.55 | 63.56 | -0.48 | -1.34 | 32.77 | 5.31 | 0.41 | 15.94 | 10.48 | -22.77 | 11.56 | 9.03 | 4.22 | 5.14 | -22.88 | -18.12 | -13.55 | 3.25 | -15.13 | 2.54 | -8.86 | -1.06 | -0.79 | -14.54 | 5.43 | 1.98 | 364.64 | 7.81 | 9.56 | 8.92 | 10.81 |
Strides Pharma Science
Strides Pharma Science
875.70
-9.55
(-1.08%)
There are new updates from the company1 day ago
View
Market Cap
8,070.69 Cr
EPS
390.55
PE Ratio
21.70
Dividend Yield
0.45 %
Industry
Healthcare52 Week High
1,675.00
52 Week Low
513.05
PB Ratio
3.20
Debt to Equity
0.94
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
Company News
View All News
Strides Pharma Science Partners with Kenox to Expand Nasal Spray Portfolio in U.S. Market
10 days ago
10 days agoStrides Pharma Science has entered into a collaboration with Kenox to expand its nasal spray product range for the U.S. market. The partnership aims to grow the company's presence in the nasal spray segment within the American pharmaceutical market.
Strides Pharma Science Limited voluntarily deregistered its non-operating step-down subsidiary, Apollo Life Sciences Holdings (Pty) Ltd, in South Africa on August 22, 2025. The deregistration is part of the company's efforts to streamline group entities and eliminate non-operating companies. Apollo South Africa had negligible financial contribution with revenue from operations of Rs. 0.22 million and negative net worth of Rs. 0.02 million for the financial year ended March 31, 2025. The company received communication about the deregistration from its local consultant on August 25, 2025, which explains the delay in intimation to the stock exchanges.
Strides Pharma Reports Strong Q1 FY26 Results with 19.5% EBITDA Margin and 81% EPS GrowthAug 04, 2025
Aug 04, 2025Strides Pharma Science delivered robust quarterly results with revenue of INR 1,120 crores and gross margins expanding 300 basis points to touch 60%. EBITDA margin reached 19.5% with operational EPS of INR 12.4, representing 81% year-on-year growth. The US business grew 7% annually, maintaining its $400 million revenue target by 2028, while other regulated markets expanded 9.2%. The company discontinued four products that didn't meet margin thresholds and received one product approval during the quarter. Operating PAT hit a record INR 114 crores with 52% EBITDA to PAT conversion. Net debt reduced to INR 1,496 crores with free cash generation of INR 26 crores. Management highlighted strong operating leverage and emphasized their beyond-generics strategy including nasal sprays and controlled substances, with the first nasal spray filing completed and patch products expected by year-end.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,648.60 | #1 3,95,554.36 | 33.89 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 52.26 | |
6,112.00 | 1,62,254.40 | 69.65 | 9,712.00 | 18.67 | 2,191 | 26.74 | 43.25 | |
1,578.20 | 1,27,472.45 | 23.36 | 28,409.50 | 7.12 | 5,291 | 9.88 | 51.20 | |
3,567.40 | 1,20,737.03 | 59.39 | 11,539.40 | 6.99 | 1,911 | 19.91 | 45.02 | |
1,322.70 | 1,10,388.72 | 19.26 | 33,741.20 | 16.73 | 5,725 | 1.26 | 60.34 | |
2,638.30 | 1,06,079.50 | 56.09 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 53.18 | |
1,047.85 | 1,05,438.23 | 22.34 | 23,511.00 | 18.55 | 4,615 | 2.60 | 62.48 | |
2,046.60 | 93,467.29 | 25.08 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 62.82 | |
30,890.00 | 65,639.09 | 45.28 | 6,684.70 | 9.64 | 1,414 | 11.55 | 39.70 | |
1,128.90 | 65,566.70 | #1 18.94 | 32,345.60 | 9.43 | 3,484 | -10.24 | 57.66 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
17.67 %
Net Income Growth
-384.50 %
Cash Flow Change
-2.38 %
ROE
-327.77 %
ROCE
280.68 %
EBITDA Margin (Avg.)
17.69 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 2,475 | 7,659 | 8,105 | 6,708 | 7,980 | 6,152 | 7,015 | 6,976 | 6,638 | 5,840 | 6,049 |
| Fixed Assets | 701 | 2,499 | 2,980 | 2,977 | 3,648 | 2,099 | 2,219 | 2,347 | 2,311 | 1,865 | 1,899 |
| Current Assets | 1,429 | 3,595 | 3,792 | 2,484 | 3,049 | 2,372 | 2,817 | 3,362 | 3,243 | 2,969 | 3,099 |
| Capital Work in Progress | 171 | 1,200 | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 162 | 207 |
| Investments | 561 | 1,260 | 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 | 409 |
| Other Assets | 1,041 | 2,700 | 2,821 | 2,524 | 3,177 | 3,091 | 3,651 | 3,798 | 3,687 | 3,510 | 3,534 |
| Total Liabilities | 2,475 | 7,659 | 8,105 | 6,708 | 7,980 | 6,152 | 7,015 | 6,976 | 6,638 | 5,840 | 6,049 |
| Current Liabilities | 1,020 | 1,940 | 3,104 | 1,899 | 2,662 | 2,545 | 2,738 | 3,412 | 2,990 | 2,879 | 2,592 |
| Non Current Liabilities | 291 | 2,813 | 2,119 | 2,191 | 2,516 | 1,012 | 1,463 | 1,181 | 1,475 | 889 | 871 |
| Total Equity | 1,164 | 2,906 | 2,882 | 2,618 | 2,802 | 2,595 | 2,814 | 2,383 | 2,173 | 2,072 | 2,587 |
| Reserve & Surplus | 1,085 | 2,774 | 2,659 | 2,374 | 2,559 | 2,438 | 2,687 | 2,269 | 2,105 | 2,034 | 2,460 |
| Share Capital | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -288 | 812 | -596 | -259 | 110 | -184 | -56 | 45 | 133 | -143 | -49 |
| Investing Activities | 50 | -2,205 | -1,222 | 570 | -145 | 1,321 | -522 | -119 | 302 | -150 | -90 |
| Operating Activities | 83 | 73 | 288 | 187 | 60 | 205 | 481 | -258 | 44 | 701 | 684 |
| Financing Activities | -421 | 2,944 | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | -693 | -643 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 29.67 % | 29.62 % | 29.60 % | 29.60 % | 30.60 % | 30.37 % | 31.07 % | 30.89 % | 28.27 % | 28.07 % | 27.78 % | 27.39 % | 25.88 % | 25.86 % | 25.84 % | 26.82 % | 28.30 % | 28.30 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.05 % | 0.05 % | 0.05 % | 0.05 % | 0.00 % | 0.00 % | 24.57 % | 26.71 % | 30.08 % | 28.48 % | 28.32 % | 28.02 % |
| DIIs | 14.82 % | 13.23 % | 14.22 % | 14.85 % | 12.40 % | 9.82 % | 13.59 % | 18.84 % | 18.29 % | 20.00 % | 18.22 % | 17.56 % | 18.04 % | 18.56 % | 18.24 % | 16.92 % | 13.72 % | 13.30 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 14.01 % | 16.64 % | 17.89 % | 20.42 % | 21.82 % | 22.29 % | 22.40 % | 22.43 % | 25.51 % | 24.93 % | 23.39 % | 22.65 % | 21.19 % | 20.87 % | 18.57 % | 20.86 % | 21.52 % | 22.10 % |
| Others | 41.49 % | 40.51 % | 38.29 % | 35.12 % | 35.19 % | 37.51 % | 32.88 % | 27.77 % | 27.86 % | 26.93 % | 30.60 % | 32.39 % | 10.32 % | 8.00 % | 7.26 % | 6.90 % | 8.14 % | 8.27 % |
| No of Share Holders | 74,074 | 96,976 | 1,06,927 | 1,25,553 | 1,33,190 | 1,34,718 | 1,30,682 | 1,23,964 | 1,20,916 | 1,12,775 | 1,01,638 | 91,182 | 84,695 | 91,917 | 96,009 | 1,14,236 | 95,125 | 92,889 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 4.5 | 2 | 3 | 0.00 | 0.00 | 0.00 | 0.00 | 2.5 | 4 |
| Dividend Yield (%) | 0.00 | 0.69 | 0.42 | 0.93 | 0.00 | 0.00 | 0.00 | 0.00 | 0.37 | 0.45 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 18 Jul 2018 |  Change Of Name | NA | 18 Jul 2018 | 157.75 | 157.75 |
| 06 Aug 2021 |  Dividend | ₹ 2.50 /share | 05 Aug 2021 | 356.19 | 342.54 |
| 04 Aug 2023 | Dividend | ₹ 1.50 /share | 04 Aug 2023 | 165.46 | 194.41 |
| 28 Aug 2023 |  Annual General Meeting | NA | 28 Aug 2023 | 193.07 | 192.90 |
| 09 Sept 2024 | Dividend | ₹ 2.50 /share | 09 Sept 2024 | 370.78 | 595.84 |
| 10 Sept 2024 |  Extraordinary General Meeting | NA | 10 Sept 2024 | 488.59 | 572.84 |
| 25 Sept 2024 | Annual General Meeting | NA | 25 Sept 2024 | 597.53 | 611.51 |
| 24 Oct 2024 |  Quarterly Result Announcement | NA | 24 Oct 2024 | 720.09 | 683.70 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 628.20 | 608.70 |
| 22 May 2025 | Quarterly Result Announcement | NA | 22 May 2025 | 663.35 | 694.95 |
| 22 Jul 2025 | Dividend | ₹ 4.00 /share | 22 Jul 2025 | 694.95 | 889.65 |
| 29 Jul 2025 | Quarterly Result Announcement | NA | 29 Jul 2025 | 877.90 | 922.50 |
| 07 Aug 2025 | Annual General Meeting | NA | 07 Aug 2025 | 865.50 | 805.65 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 26, 2025
Aug 26, 2025Deregistration Of A Non-Operating Step-Down Subsidiary Of The Company In South AfricaAug 25, 2025
Aug 25, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Aug 07, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 29, 2025
Jul 29, 2025Board Meeting Outcome for Allotment Of Shares Under ESOP SchemeJul 29, 2025
Jul 29, 2025Amendment To Code Of Fair Disclosure Of UPSIJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 29, 2025
Jul 29, 2025Financial Results (Consolidated & Standalone) For The Quarter Ended June 30 2025Jul 29, 2025
Jul 29, 2025Change In Statutory Auditors Of Material Subsidiary Of The Company In UKJul 28, 2025
Jul 28, 2025Reminder To Shareholders About Transfer Of Equity Shares Relating To Unclaimed Dividend Of The Company To Investor Education And Protection Fund (IEPF)Jul 26, 2025
Jul 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2025
Jul 23, 2025Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 22, 2025
Jul 22, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 11, 2025
Jul 11, 2025Reg. 34 (1) Annual Report.Jul 11, 2025
Jul 11, 2025Notice Of 34Th Annual General MeetingJul 11, 2025
Jul 11, 2025No Objection Letter Received From Stock Exchanges.Jul 10, 2025
Jul 10, 2025Intimation Regarding Communication To Shareholders On TDS For Final Dividend For FY 2024-25Jul 10, 2025
Jul 10, 2025Intimation Regarding Communication To Shareholders On TDS For Final Dividend For FY 2024-25Jul 10, 2025
Jul 10, 2025Intimation To Members About Record Date For The Purpose Of Final Dividend For FY25.Jul 09, 2025
Jul 09, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Intimation Pursuant To Regulation 31AJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-RestructuringJun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 27, 2025
May 27, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
May 27, 2025Intimation Pursuant To Regulation 31A Of The Sebl (Listing Obligations And Disclosure Requirements) Regulations 2015 Regarding Promoter ReclassificationMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 22, 2025
May 22, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On May 22 2025May 22, 2025
May 22, 2025Update On Promoters Reclassification RequestMay 22, 2025
May 22, 2025Appointment Of Secretarial AuditorMay 22, 2025
May 22, 2025Corporate Action-Board approves DividendMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 22, 2025
May 22, 2025Outcome Of Board Meeting Of The Company Held On May 22 2025May 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Scheme of ArrangementMay 15, 2025
May 15, 2025Intimation Under Regulation 31A Of SEBI Listing RegulationsMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 15, 2025
May 15, 2025Board Meeting Intimation for Intimation On Board MeetingMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 10, 2025
May 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 30, 2025
Apr 30, 2025Strides Acquires Identified Andas From Nostrum Laboratories Inc. USAApr 29, 2025
Apr 29, 2025Announcement under Regulation 30 (LODR)-AcquisitionApr 11, 2025
Apr 11, 2025Technical Indicators
RSI(14)
Neutral 51.42
ATR(14)
Less Volatile 29.74
STOCH(9,6)
Neutral 38.45
STOCH RSI(14)
Neutral 32.62
MACD(12,26)
Bearish -0.28
ADX(14)
Strong Trend 27.09
UO(9)
Bearish 39.97
ROC(12)
Downtrend And Accelerating -1.28
WillR(14)
Neutral -52.73
Mutual Fund Holdings
Bandhan Small Cap Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
ITI Pharma and Healthcare Fund Direct - Growth 
Samco Multi Cap Fund Direct-Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Aditya Birla Sun Life Value Direct Fund-Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
JM ELSS Tax Saver Fund Direct Plan-Growth 
Axis Small Cap Fund Direct-Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
